A new strategy strengthens the bond between the T cell and a target tumor cell, improving the cytotoxic function of the T cell.
UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...
Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea’s proprietary in vivo CAR T platformPeer-reviewed publication ...
Wistar Institute scientists have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity ...
The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...
UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T ...
Researchers at UC San Francisco have now developed a way to reprogram these cancer-fighting cells directly inside the body. This new method could remove the need for external manufacturing, ...
The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a ...
Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...
A new study published in the journal Nature reports results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3 (GPC3). Researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results